Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Qu, D. Lambracht-Washington, Min Fu, T. Eagar, O. Stüve, R. Rosenberg (2010)
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.Vaccine, 28 32
D. Lambracht-Washington, Min Fu, P. Frost, R. Rosenberg (2017)
Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimerAlzheimer's Research & Therapy, 9
R. Rosenberg, Min Fu, D. Lambracht-Washington (2018)
Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathologyAlzheimer's Research & Therapy, 10
D. Lambracht-Washington, R. Rosenberg (2015)
Co-stimulation with TNF receptor superfamily 4/25 antibodies enhances in-vivo expansion of CD4+CD25+Foxp3+ T cells (Tregs) in a mouse study for active DNA Aβ42 immunotherapyJournal of Neuroimmunology, 278
W. Zago, Manuel Buttini, T. Comery, Christopher Nishioka, S. Gardai, P. Seubert, D. Games, F. Bard, D. Schenk, G. Kinney (2012)
Neutralization of Soluble, Synaptotoxic Amyloid β Species by Antibodies Is Epitope SpecificThe Journal of Neuroscience, 32
D. Lambracht-Washington, B. Qu, Min Fu, T. Eagar, O. Stüve, R. Rosenberg (2009)
DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.JAMA, 302 16
Lambracht-Washington (2017)
Evaluation of a DNA A�42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA A�42 trimer.Alzheimers Res Ther, 9
D. Lambracht-Washington, R. Rosenberg (2015)
DNA Aβ42 immunization generates a multivalent vaccine: Antibodies in plasma of active full-length DNA Aβ42 immunized mice show polyclonal Aβ42 peptide bindingAlzheimer's & Dementia, 11
S. Gilman, M. Koller, R. Black, L. Jenkins, S. Griffith, Nick Fox, L. Eisner, L. Kirby, M. Rovira, F. Forette, J. Orgogozo (2005)
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trialNeurology, 64
Rosenberg (2018)
Active full-length DNA A�42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology.Alzheimers Res Ther, 10
C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, Vivienne Hopkins, A. Bayer, Roy Jones, R. Bullock, S. Love, J. Neal, E. Zotova, J. Nicoll (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trialThe Lancet, 372
This Viewpoint argues that there is a possibility of finding a path forward in Alzheimer disease prevention with the DNA amyloid β 1-42 timer vaccine that warrants its evaluation in a clinical trial.
JAMA Neurology – American Medical Association
Published: Mar 9, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.